Analysis of the Efficacy of Calcium Channel Blockers for Integrated Relaxation Pressure Values on High-resolution Manometry
| Case | Sex | Age (yr) | Type of achalasia | IRP mmHg (before administration) | Medication (dosage, mg/day) | Adverse events | Symptoms (after) | IRP mmHg (after administration) |
|---|---|---|---|---|---|---|---|---|
| Case 1 | Female | 40 | Type II | 33.4 | Nifedipine (10) | Nausea, vertigo | No change | 35.5 (failure) |
| Case 2 | Male | 39 | Type I | 32.1 | Nifedipine (10) | No change | Unmeasurable | |
| Case 3 | Female | 50 | Type I | 20.6 | Nifedipine (20) | No change | 28.3 | |
| Case 4 | Female | 52 | Type I | 24.3 | Nifedipine (10) | Improved | 34.7 | |
| Case 5 | Female | 46 | Type I | 34.5 | Nifedipine (10) | Improved | 35.9 | |
| Case 6 | Male | 37 | Type II | 30.7 | Nifedipine (10) | Nausea, headache | (Failure) | |
| Case 7 | Male | 49 | Type II | 29.4 | Nifedipine (20) | Improved | 28.8 | |
| Case 8 | Female | 46 | Type II | 23.2 | Diltiazem (60) | Improved | 24.2 | |
| Case 9 | Male | 72 | Type I | 25.1 | Diltiazem (90) | No change | 26.6 |
Integrated relaxation pressure (IRP) values have no significant difference on calcium channel blocker use (
Failure: in 2 cases, due to adverse events, including nausea, vertigo, and headache, these patients could not continue the medication therapy. Unmeasurable, due to the tight lower esophageal sphincter (LES) even after the medication therapy, the catheter did not pass through the LES.
IRP, integrated relaxation pressure.